Source: Good Stock Invest

Terns Pharmaceuticals: GENFIT: 2019 annual financial results and update on the activities of the Company

RESOLVE-IT Phase 3 clinical trial interim results expected by the end of May 2020 Cash position at € 277 million at 12/31/2019 (vs € 207 [...]L'article GENFIT: 2019 annual financial results and update on the activities of the Company est apparu en premier sur Good Stock Invest.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Senthil Sundaram's photo - CEO of Terns

CEO

Senthil Sundaram

CEO Approval Rating

90/100

Terns is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer and liver diseases. Read more